Welcome to our dedicated page for Sigilon Therapeutics news (Ticker: SGTX), a resource for investors and traders seeking the latest updates and insights on Sigilon Therapeutics stock.
Sigilon Therapeutics, Inc. (NASDAQ: SGTX) is a clinical-stage biopharmaceutical company pioneering cell-based therapies for chronic diseases through its Shielded Living Therapeutics™ platform. This page provides investors and medical innovators with essential updates on SGTX's strategic developments, including its acquisition by Eli Lilly to advance diabetes treatment research.
Access timely updates on clinical milestones, partnership expansions, and therapeutic innovations. Key content includes progress reports on SIG-002 for type 1 diabetes, updates on the Lilly collaboration, and analyses of the Afibromer™ biomaterials technology. All press releases are vetted for accuracy and compliance.
Bookmark this page to monitor how Sigilon's acquisition accelerates development of functional cures while maintaining its Cambridge-based research focus. Check regularly for authoritative updates on cell therapy advancements and strategic corporate decisions shaping the future of chronic disease treatment.
Sigilon Therapeutics (NASDAQ:SGTX) announced that CEO Rogerio Vivaldi, M.D., will present a corporate overview at the BofA Securities 2021 Healthcare Conference on May 12 at 3:30 p.m. EDT. This virtual presentation aims to highlight the company's innovative Shielded Living Therapeutics™ platform, which develops non-viral engineered cell-based therapies for chronic diseases like hemophilia and diabetes. Interested investors can access the live webcast on the company's website, with a replay available for 90 days post-event.
Sigilon Therapeutics (NASDAQ:SGTX) announced four abstracts will be presented at the ASGCT 24th Annual Meeting, showcasing initial results from preclinical studies of its Shielded Living Therapeutics (SLTx) platform. These include studies on immune-mediated hepatitis and hypoparathyroidism, highlighting SLTx's potential to address current therapy limitations. Presentations will be available starting May 11, 2021. Sigilon specializes in non-viral engineered cell therapies designed for chronic diseases and uses Afibromer biomaterials for protection against immune rejection.
Sigilon Therapeutics (NASDAQ:SGTX) announced that its President and CEO, Rogerio Vivaldi, M.D., will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 9:30 a.m. EDT. The company focuses on developing functional cures for chronic diseases using its Shielded Living Therapeutics™ platform. Sigilon's non-viral engineered cell-based therapies target conditions like hemophilia and diabetes, employing Afibromer™ biomaterials to protect cells from immune rejection.
Sigilon Therapeutics (NASDAQ:SGTX) reported financial results for Q4 and full year 2020, marking a transformative year for the company. Highlights include the clearance of SIG-001 for hemophilia A and the dosing of the first patients in a Phase 1/2 study. The company raised $144.9 million from its IPO in December 2020, enhancing its cash position to $202.2 million. R&D expenses increased to $53.5 million for 2020, with a net loss of $54.6 million. Looking ahead, Sigilon plans multiple regulatory filings in 2021 and aims to advance various candidates through clinical development.
Sigilon Therapeutics (NASDAQ:SGTX) announced the FDA granted orphan drug designation to SIG-007 for treating Fabry disease, a rare lysosomal disorder. This genetically modified therapy aims to provide continuous enzyme release, potentially alleviating treatment burdens associated with current intravenous therapies that may cause severe complications. This marks Sigilon's third orphan drug designation, enhancing their commitment to chronic disease treatment. The company plans to file multiple INDs in the next 12-24 months, positioning SIG-007 for future clinical use and market exclusivity benefits.
Sigilon Therapeutics, Inc. (NASDAQ:SGTX) announced that its President and CEO, Rogerio Vivaldi, M.D., will present a corporate overview at the Barclays Global Healthcare Conference on March 11, 2021, at 10:55 a.m. EST. The presentation will be virtual, and a live webcast can be accessed on the company's website. Sigilon focuses on developing functional cures for chronic diseases using its Shielded Living Therapeutics™ platform, offering engineered cell-based therapies for conditions like hemophilia and diabetes. These therapies utilize Afibromer™ biomaterials to protect against immune rejection.
Sigilon Therapeutics has reported promising results from preclinical studies on its Shielded Living Therapeutics™ platform during the 17th Annual WORLD Symposium. The research focuses on lysosomal diseases such as MPS-1, Fabry, MPS-2, and MPS-6. The platform demonstrated sustained release of proteins and the ability to reach multiple organ systems, potentially improving treatment outcomes compared to standard therapies. An oral presentation on SIG-018 for MPS II and several e-posters are scheduled for February 11, 2021.
Sigilon Therapeutics (NASDAQ: SGTX) will present an overview of its innovative Shielded Living Therapeutics™ platform at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 3:40 p.m. EST. CEO Rogerio Vivaldi, M.D., will lead the presentation, available via live webcast on the company’s website. Sigilon aims to develop functional cures for chronic diseases like hemophilia and diabetes using engineered human cells protected from immune rejection. A replay of the presentation will be accessible post-event.
Sigilon Therapeutics (NASDAQ: SGTX) announced that the FDA granted Orphan Drug designation to SIG-005 for treating mucopolysaccharidosis type I (MPS-1), a lysosomal storage disease. This designation allows for various development incentives, including tax credits and seven years of market exclusivity post-approval. The company plans to initiate a Phase 1/2 clinical trial in the second half of 2021, aiming to explore the potential of SIG-005, which modifies human cells to express the necessary enzyme for MPS-1 treatment.
Sigilon Therapeutics (Nasdaq: SGTX) successfully closed its upsized IPO, offering 8,050,000 shares at $18.00 each, yielding gross proceeds of $144.9 million. The offering included the underwriters' full exercise of options for an additional 1,050,000 shares. All shares were sold by Sigilon. This financing supports the company's mission to develop functional cures for chronic diseases via its Shielded Living Therapeutics™ platform, utilizing engineered human cells to provide essential proteins for conditions like hemophilia and diabetes.
